Search Results - "Chesnais, V."

High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells by Poulain, L, Sujobert, P, Zylbersztejn, F, Barreau, S, Stuani, L, Lambert, M, Palama, T L, Chesnais, V, Birsen, R, Vergez, F, Farge, T, Chenevier-Gobeaux, C, Fraisse, M, Bouillaud, F, Debeissat, C, Herault, O, Récher, C, Lacombe, C, Fontenay, M, Mayeux, P, Maciel, T T, Portais, J-C, Sarry, J-E, Tamburini, J, Bouscary, D, Chapuis, N

“…Alterations in metabolic activities are cancer hallmarks that offer a wide range of new therapeutic opportunities. Here we decipher the interplay between…”
Get full text

SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias by Damm, F, Itzykson, R, Kosmider, O, Droin, N, Renneville, A, Chesnais, V, Gelsi-Boyer, V, de Botton, S, Vey, N, Preudhomme, C, Clavert, A, Delabesse, E, Park, S, Birnbaum, D, Fontenay, M, Bernard, O A, Solary, E

Get full text

Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling by Kerdivel, G, Chesnais, V, Becht, E, Toma, A, Cagnard, N, Dumont, F, Rousseau, A, Fenaux, P, Chevret, S, Chapuis, N, Boeva, V, Fridman, W H, Fontenay, M, Kosmider, O

Get full text

Mutation of the colony-stimulating factor-3 receptor gene is a rare event with poor prognosis in chronic myelomonocytic leukemia by Kosmider, O, Itzykson, R, Chesnais, V, Lasho, T, Laborde, R, Knudson, R, Gauthier, A, Merlevede, J, Ades, L, Morabito, M, Fontenay, M, Tefferi, A, Droin, N, Solary, E

Get full text

A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q) by Sardnal, V, Rouquette, A, Kaltenbach, S, Bally, C, Chesnais, V, Leschi, C, Ades, L, Santini, V, Park, S, Toma, A, Fenaux, P, Dreyfus, F, Fontenay, M, Kosmider, O

Get full text

159 CSNK1A1 IS NORMALLY EXPRESSED AND UNMUTATED IN MDS PATIENTS WITHOUT DEL(5Q) BEFORE AND UNDER TREATMENT WITH LENALIDOMIDE by Chesnais, V, Passet, M, Bondu, S, Toma, A, Fenaux, P, Dreyfus, F, Fontenay, M, Kosmider, O, GFM

Get full text

148 CLONAL EVOLUTION OF HEMATOPOIETIC STEM CELL UNDER TREATMENT BY LENALIDOMIDE IN NON DEL(5Q) MDS by Chesnais, V, Renneville, A, Toma, A, Passet, M, Gauthier, A, Delaunay, J, Rose, C, Stamatoullas, A, Beyne-Rauzy, O, Fenaux, P, Dreyfus, F, Preudhomme, C, Fontenay, M, Kosmider, O

Get full text

O-007 BCOR and BCORL1 mutations in myelodysplasia: Prevalence, prognosis and clonal hierarchy by Damm, F, Chesnais, V, Nagata, Y, Yoshida, K, Okuno, Y, Birnbaum, D, Ogawa, S, Bernard, O.A, Fontenay, M, Kosmider, O

Get full text

Topic: AS04-MDS Biology and Pathogenesis/AS04e-Spliceosome machinery: DNA REPLICATION STRESS DUE TO LOSS OF R-LOOPS IN MYELODYSPLASTIC SYNDROMES WITH SF3B1 MUTATION by Rombaut, D., Lefevre, C., Farhat, B., Bondu, S., Letessier, A., Lesieur-Pasquier, A., Castillo-Guzman, D., Leduc, M., Hartono, S., Chesnais, V., Mangione, R., Boussaid, I., Houy, A., Bouscary, D., Willems, L., Chapuis, N., Kosmider, O., Park, S., Raynaud, S., Cluzeau, T., Clappier, E., Fenaux, P., Ades, L., Margueron, R., Wassef, M., Alsafadi, S., Solary, E., Constantinou, A., Stern, M.-H., Palancade, B., Droin, N., Miotto, B., Chédin, F., Fontenay, M.

Get full text

Pain reactivity and plasma beta-endorphin in children and adolescents with autistic disorder by Poulain, L., Sujobert, P., Zylbersztejn, F., Barreau, S., Lambert, M., Chesnais, V., Birsen, R, Vergez, F., Farge, T., Chenevier-Gobeaux, C., Fraisse, M., Bouillaud, F., Debeissat, C., Herault, O., Récher, C., Lacombe, C., Fontenay, M., Mayeux, P., Maciel, T. T., Sarry, J.E., Tamburini, J., Bouscary, D., Chapuis, N.

“…Background: Reports of reduced pain sensitivity in autism have prompted opioid theories of autism and have practical care ramifications. Our objective was to…”
Get full text